Sipuleucel-T API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Sipuleucel-T API 917381-47-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Sipuleucel-T. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Sipuleucel-T
- Synonyms:
- Sipuleucel-T , Sipuleucel-T , Sipuleucel-T
- Cas Number:
- 917381-47-6
- DrugBank number:
- DB06688
- Unique Ingredient Identifier:
- 8Q622VDR18
About Sipuleucel-T
Want to know more about Sipuleucel-T? Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient.
In metastatic prostate cancer, it has extended survival by median. months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the USA Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
You can find more info about this product by clicking on the DB ID above.
